Bellicum Pharmaceuticals, Inc. (BLCM) Stock

About Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.

Bellicum Pharmaceuticals, Inc. is headquartered in US.

Bellicum Pharmaceuticals, Inc. (BLCM) stock trades at $0.07 with a market capitalization of $778326. The stock is valued at a price-to-earnings (P/E) ratio of -0.09, price-to-book of 1.14, price-to-sales of 0.52. Over the past 52 weeks the stock has ranged between $0.06 and $1.31, and currently trades 94.7% below its 52-week high.

On profitability, Bellicum Pharmaceuticals, Inc. generates a return on equity (ROE) of -189.12%, return on capital employed of -134.56%, an operating margin of -1350.00%, a net profit margin of -1250.00%.

Official website: www.bellicum.com